Furthermore, organoids derived from GC patients were used to demonstrate the relationship between NAT10 and KLF5, and the expression of KLF5 was found to be augmented by NAT10 overexpression and inhibited by the NAT10 inhibitor Remodelin (Figure 5K). Here, KLF5 is linked to gastric cancer.